Mr. Wheatley’s relevant experience includes advising clients in complying with in-depth merger review investigations (Second Requests) before the U.S. antitrust authorities:
- Spark Therapeutics in its $4.3 billion sale of its burgeoning gene therapies to Roche Group. The Federal Trade Commission cleared this transaction with a 5-0 vote.
- Beth Israel Deaconess Medical Center, Lahey Health System, New England Baptist Hospital, Mount Auburn Hospital, and Seacoast Regional Health System in their $5+ billion merger to create Beth Israel Lahey Health, the second largest healthcare system in the Eastern Massachusetts area. Approvals were required from both the FTC and multiple state-level agencies, including the Office of the Attorney General of Massachusetts. The Boston Globe described the combination as “the most significant health care deal in Massachusetts” in decades.
- Rainmaker in its $300 million sale of its LRO software and related assets to RealPage. After concluding compliance with a Second Request process, this transaction was cleared by the DOJ without condition.
Mr. Wheatley’s work in assuring antitrust clearance in publicly announced transactions that were required to be reported under the HSR Act include:
- Ansys in its $775 million purchase of Livermore Software Technology Company
- Truck Hero International, a leading automotive accessories provider, in its acquisition of Lund International, another leading automotive accessories provider
- TurnItIn in its $1.75 billion sale to Advance Publications
- The independent directors of Sprint Corporation in its $59 billion merger with T-Mobile USA
- PillPack, Inc. in its $1 billion acquisition by Amazon
- Qualtrics in its $8 billion acquisition by SAP SE
- Eventbrite in its $200 million purchase of Ticketfly
- Continuum Parent, LLC in its sale to ConnectWise
- BlueTarp Financial, Inc. in its acquisition by Capital One, N.A.
- Monotype in its $825 million sale to HGGC
- Semma Therapeutics in its $950 million sale to Vertex
- BeiGene in its $2.7 billion share sale to Amgen as part of a global strategic oncology collaboration
Mr. Wheatley’s other antitrust experience includes:
- Representing third-party witnesses in FTC and DOJ antitrust investigations and in civil antitrust litigation.
- Counseling companies and trade associations on antitrust compliance.
- Defending health insurer in multidistrict ligation alleging antitrust violations under Sections 1 and 2 of the Sherman Act*
- Defending major energy company in multi-state investigations and litigation alleging fraud, unjust enrichment, and false claims*
* Denotes experience prior to joining Goodwin.
Mr. Wheatley is a member of the American Bar Association’s Section of Antitrust Law.
Prior to joining Goodwin, Mr. Wheatley was an associate at a Chambers-ranked antitrust practice in Washington, D.C. He also served as a law clerk to the Honorable Ted Stewart of the United States District Court for the District of Utah. While in law school, he worked as a law clerk at the Federal Trade Commission in the Bureau of Competition and in the office of Commissioner Maureen K. Ohlhausen.